2023
Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors
Kahn A, Perry C, Etts K, Kluger H, Sznol M. Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors. The Oncologist 2023, 29: e507-e513. PMID: 37971411, PMCID: PMC10994263, DOI: 10.1093/oncolo/oyad300.Peer-Reviewed Original ResearchBRAF/MEK inhibitorsBRAF/MEK inhibitionImmune checkpoint inhibitorsBRAFV600E/K mutationsMEK inhibitorsCheckpoint inhibitorsClinical variablesMEK inhibitionRetrospective single-institution analysisIpilimumab/nivolumabFirst-line settingFirst-line therapyFirst-line treatmentMetastatic melanoma patientsLong-term outcomesPretreatment clinical variablesSingle-institution analysisStratification of patientsK mutationCombined BRAFECOG PSMedian OSRECIST 1.1Immunotherapy regimenClinical characteristics
2020
Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.
Sarnaik A, Khushalani N, Chesney J, Lewis K, Medina T, Kluger H, Thomas S, Domingo Musibay E, Pavlick A, Whitman E, Martin-Algarra S, Corrie P, Lutzky J, Hamid O, Wu R, Shi W, Fardis M, Weber J, Larkin J, Kirkwood J. Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies. Journal Of Clinical Oncology 2020, 38: 10006-10006. DOI: 10.1200/jco.2020.38.15_suppl.10006.Peer-Reviewed Original ResearchBRAF/MEK inhibitorsMultiple prior therapiesMedian DoRPrior therapyCheckpoint inhibitorsAdvanced melanomaMelanoma patientsMedian studyMEK inhibitorsBaseline tumor burdenCohort 2 patientsIL-2 regimensAdverse event profileLong-term followMetastatic melanoma patientsIL-2 dosesAdoptive cell therapyUnresectable metastatic melanomaBaseline disease burdenBody's natural defensesAnti-cancer therapyAutologous tumorRECIST v1.1TIL productionAdvanced disease
2019
Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1.
Sarnaik A, Khushalani N, Chesney J, Kluger H, Curti B, Lewis K, Thomas S, Whitman E, Hamid O, Lutzky J, Pavlick A, Weber J, Larkin J, Barton D, Yung L, Suzuki S, Fardis M, Kirkwood J. Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1. Journal Of Clinical Oncology 2019, 37: 2518-2518. DOI: 10.1200/jco.2019.37.15_suppl.2518.Peer-Reviewed Original ResearchBRAF/MEK inhibitorsTumor-infiltrating lymphocytesMetastatic melanoma patientsMelanoma patientsTIL therapyPrior therapyAdvanced metastatic melanoma patientsDurable long-term responsesMEK inhibitorsBaseline tumor burdenCohort 2 patientsMultiple prior therapiesTIL infusion productsIL-2 dosesAdoptive cell therapyUnresectable metastatic melanomaBaseline disease burdenOverall disease controlAutologous tumorTIL infusionTIL productionMedian followCheckpoint inhibitorsUnresectable melanomaAdverse eventsSafety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients previously treated with at least one prior systemic therapy.
Sarnaik A, Thomas S, Davar D, Kirkwood J, Kluger H, Lutzky J, Wilson M, Pavlick A, Curti B, Whitman E, Phan G, Ernstoff M, Takamura K, Barton D, Suzuki S, Karyampudi L, Samberg N, Fardis M, Chesney J. Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients previously treated with at least one prior systemic therapy. Journal Of Clinical Oncology 2019, 37: 136-136. DOI: 10.1200/jco.2019.37.8_suppl.136.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesBRAF/MEK inhibitorsMetastatic melanoma patientsMetastatic melanomaPrior therapyCheckpoint inhibitorsMelanoma patientsIL-2Advanced metastatic melanoma patientsHigh-dose IL-2MEK inhibitorsBaseline tumor burdenCohort 2 patientsDose IL-2Frequency of AEsPrior systemic therapyAdoptive cell therapyUnresectable metastatic melanomaPreliminary dataAutologous tumorLymphodepletion regimenTIL treatmentMedian followProgressive diseaseComplete response